Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Nutrition supply human beings with the essential amount of carbohydrates, proteins, water, fats, vitamins, and minerals for proper cellular functioning and physiological activities and to maintain energy balance in the body. Clinical nutrition is recommended for patients of all ages including infants, adults, and geriatric, who are susceptible to conditions such as metabolic syndrome, nutrition for patients undergoing surgery or nutrition for patients post-surgery, and others. These factors have led to an increase in demand for clinical nutrition products. According to the American Diabetes Association report 2019, 34.2 million Americans or 10.5% of the population had diabetes in 2018 and according to the same source, around 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents. Clinical nutrition is segmented into two different types such as enteral nutrition and parental nutrition, and is important for management of certain chronic conditions such as diabetes, obesity, constipation, malabsorption, indigestion, and others. It also helps to maintain healthy lifestyle, improves appetite and food intake, lowers the risk for nutrient deficiencies, and other health conditions.
The U.S. clinical nutrition market is estimated to be valued at US$ 4,148.9 million in 2020 and is expected to exhibit a CAGR of 5.8% during the forecast period (2020-2027).
Figure 1. U.S. Clinical Nutrition Market Share (%) in Terms of Value, By Application, 2020
The rising prevalence of chronic diseases is expected to drive the market growth during the forecast period
The increasing prevalence of cancer in the U.S. is expected to drive the market growth over the forecast period. For instance, according to the American Cancer Society report September 2020, Breast cancer is one of the most common type of cancer in the U.S., with 279,100 new cases expected in the U.S. in 2020.
U.S. Clinical Nutrition Market Report Coverage
||Market Size in 2020:
||US$ 4,148.9 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 6,161.4 Mn
- By Nutrition Type:
- Enteral Nutrition: Standard Nutrition, Disease Specific Nutrition.
- Parenteral Nutrition: Amino Acid, Carbohydrates, Vitamins and Minerals, Others.
- By Form: Powder, Liquid, Others.
- By Age Group: Infant Nutrition, Adult Nutrition, Geriatric Nutrition.
- By Application: Diabetes, Cancer, Critical Care, Neurological Disorder, Metabolic Syndrome, Gastrointestinal Diseases, Other Applications
- By End User: Hospitals, Ambulatory Surgical Centers, Long Term Care Facilities
Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Nestlé S.A., DANONE S.A., B. Braun Melsungen AG, Mead Johnson & Company LLC, and Perrigo Company PLC
- Rising prevalence of chronic diseases
- Increasing number of product launches
- Government initiatives, investments, and funding for clinical nutrition research
|Restraints & Challenges:
- Side effects of clinical nutrition
- High cost nutritional therapy in ICU patients
Figure 2. U.S. Clinical Nutrition Market Share (%), by End User, 2020
Increasing government initiatives to spread awareness about clinical nutrition are expected to drive the market growth during the forecast period
Several government and non-government programs are carried out in U.S, in order to spread awareness among people about U.S. Clinical Nutrition Market, which is expected to drive the market growth during the forecast period.
For instance, in October 2015, the National Association of Nutrition and Aging Services Programs (NANASP) announced an increase in the 2-year budget agreement starting in October 2015 and ending in September 2017. Moreover, under the Older Americans Act (OAA) 2017, US$ 83.7 billion for the Supplemental Nutrition Assistance Program (SNAP) was allocated by the then president of the U.S., Mr. Barack Obama.
Thus, increasing awareness about clinical nutrition is expected to drive the market growth during the forecast period.
U.S. Clinical Nutrition Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 109 million infected individuals worldwide as of February 17, 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players operating in the U.S. Clinical Nutrition Market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing clinical nutritional products due to irregularities in transportation. Moreover, distributors of clinical nutritional product are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
U.S. Clinical Nutrition Market: Restraint
The major factors that is expected to hinder growth of the U.S. clinical nutrition market include side effects and complications caused by excessive consumption of products indicated for clinical nutrition. Excess consumption of any nutritional product can lead to life threating conditions. For instance, excessive consumption of parenteral nutritional therapy can lead to serious and life threating conditions such as liver dysfunction. The serious side effects associated with clinical nutrition include high blood pressure, high cholesterol, heart disease, stroke, and osteoporosis, and these factors are expected to restrain the adoption of clinical nutrition.
Moreover, higher cost of the treatment for critical ICU patients undergoing nutritional therapy is expected to hamper the U.S. clinical nutrition market growth during the forecast period. For instance, according to a study published in the BioMed Central (BMC) in year 2019, patients who survive ICU suffer from severe, prolonged functional disabilities and thus, many patients are likely to be discharged to post-acute care facilities, where the patient requires nutritional support and this could incur costs of approximately US$ 3.5 million/ depending on functioning of patient, in the U.S.
Major players operating in the U.S. clinical nutrition market include Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Nestlé S.A., DANONE S.A., B. Braun Melsungen AG, Mead Johnson & Company LLC, and Perrigo Company PLC.